Patents Examined by Mindy Fleisher
  • Patent number: 5686263
    Abstract: Methods are provided for the identification and use of endogenous nucleic acid sequences for homologous recombination and targeted integration of heterologous nucleic acid sequences. These methods are useful for introduction of nucleic acid into cells or tissue for gene therapy, or for the preparation of transgenic animals. Methods are also provided for enhancing the yield of genes of interest from recombinant cell culture lines.
    Type: Grant
    Filed: January 28, 1994
    Date of Patent: November 11, 1997
    Assignee: Genentech, Inc.
    Inventor: Florian M. Wurm
  • Patent number: 5683893
    Abstract: A mutant AOX2 promoter obtained by mutating a sequence of natural AOX2 promoter in a manner comprising at least one of the three mutation modes of (1) a region extending upstream from nucleotide 1187 inclusive and comprising at least nucleotides 845-960 is deleted, (2) nucleotide(s) is(are) replaced in region(s) in nucleotides 1274-1314, and (3) new oligonucleotide(s) is (are) inserted in region(s) in nucleotides 1274-1314, a vector carrying said mutant AOX2 promoter, a transformant into which said vector has been introduced, and a method for producing a heterologous protein, which comprises cultivating said transformant. The promoter of the present invention has remarkably enhanced activity as compared with natural AOX2 promoter, and is highly useful as a promoter to be carried in an expression vector allowing heterologous protein expression. In addition, the vector and the transformant of the invention can efficiently express and produce various useful heterologous proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 4, 1997
    Assignee: The Green Cross Corporation
    Inventors: Hideyuki Ohi, Masami Miura, Shusei Uno, Masako Chuganji, Ryuji Hiramatsu, Takao Ohmura
  • Patent number: 5681737
    Abstract: Six sets of Salmonella typhimurium strains are provided, all strains having low spontaneous mutation rates, and each set being sensitive to and diagnostic of one of the six possible base substitutions in DNA. Also provided are methods for making and using these S. typhimurium strains to detect, and establish the type of specific base substitution mutation induced by, mutagenic agents.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: October 28, 1997
    Assignee: The Regents of the University of California
    Inventors: Pauline Gee, Dorothy M. Maron, Bruce N. Ames
  • Patent number: 5679352
    Abstract: Synthetic peptides have an amino acid sequence corresponding to at least one antigenic determinant of at least one protein, usually a structural protein, particularly the P1, P2 and P6 protein, of Haemophilus influenzae (Hi), particularly type b, and are used as is, in chimeric T-B form, in lipidated form, linked to a carrier molecule, particularly a synthetic PRP molecule and/or polymerized to form molecular aggregates, in vaccines against Hi.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 21, 1997
    Assignee: Connaught Laboratories Limited
    Inventors: Pele Chong, Ali Kandil, Charles Sia, Michel Klein
  • Patent number: 5679517
    Abstract: Methods for identifying the existence, and optionally the location, of chromosomal aberration(s) in the genome of an organism are disclosed. Intact, chromosomal DNA is hybridized with one or more clones constructed from chromosomal DNA derived from an organism of the same species as the organism to be tested. By identifying the existence of a chromosomal aberration, the susceptibility of an individual to certain disease states can be predicted, and/or the nature of a given disease state can be ascertained with greater certainty.
    Type: Grant
    Filed: October 18, 1994
    Date of Patent: October 21, 1997
    Assignee: The Salk Institute For Biological Studies
    Inventors: Glen A. Evans, Licia Selleri, Gary G. Hermanson
  • Patent number: 5679540
    Abstract: This invention relates to a purified isolated DNA fragment of Bacteroides fragilis comprising a sequence for an operon containing two genes designated rprX and rprY. These genes encode two signal transducing regulatory proteins designated RprX and RprY. This invention further relates to the proteins RprX and RprY encoded by the operon. RprX and RprY affect the normal regulation of OmpF by OmpR and EnvZ.
    Type: Grant
    Filed: February 26, 1993
    Date of Patent: October 21, 1997
    Assignee: American Cyanamid Company
    Inventor: Beth Ann Rasmussen
  • Patent number: 5677153
    Abstract: The invention relates to methods and mutation linkers to modify DNA, to methods for producing libraries containing a multiplicity of modified DNA, and to methods for using such libraries for screening modified proteins encoded by such DNA. The DNA targeted for modification typically encodes a polypeptide such as an enzyme. The libraries are used to determine the effect of such modification or the interaction of the modified polypeptides with a target. In preferred embodiments, the invention relates to methods for making and using libraries containing DNA encoding modified antibiotic hydrolases to screen antibiotics against one or more of the modified antibiotic hydrolases produced by such libraries. Susceptibility or lack of susceptibility of an antibiotic to neutralization provides an indication of whether wild-type antibiotic hydrolases are likely to mutate to confer resistance to the antibiotic.
    Type: Grant
    Filed: November 29, 1994
    Date of Patent: October 14, 1997
    Assignee: Genentech, Inc.
    Inventors: David Botstein, Timothy Palzkill
  • Patent number: 5674844
    Abstract: The invention is a treatment for increasing the bone mass or preventing bone loss in an individual afflicted with a bone disease which includes administering to the individual a morphogen in a therapeutically effective amount so as to maintain or stimulate bone formation.
    Type: Grant
    Filed: March 20, 1995
    Date of Patent: October 7, 1997
    Assignee: Creative BioMolecules, Inc.
    Inventors: Thangavel Kuberasampath, Charles M. Cohen, Hermann Oppermann, Engin Ozkaynak, David C. Rueger, Roy H. L. Pang
  • Patent number: 5674729
    Abstract: A process for the de novo synthesis of a picornavirus using a cell-free medium has been developed. The cell-free medium is prepared from a lysate of mammalian cells from which the nuclei and mitochondria has been removed, endogenous mRNA deactivated and supplemented with nucleoside triphosphates, tRNA, amino acids and precursors necessary for generating proteins. The genomic RNA of the picornavirus or rhinovirus is added to the cell-free medium and after incubation at about C. to C. of from about 4 to 24 hours infectious, mature virus particles are formed.
    Type: Grant
    Filed: June 30, 1994
    Date of Patent: October 7, 1997
    Assignee: Research Foundation of State University of New York
    Inventors: Eckard Wimmer, Akhteruzzaman Molla, Aniko V. Paul
  • Patent number: 5674992
    Abstract: A nucleotide and deduced amino acid sequence of a cDNA encoding the Arabidopsis thaliana RecA protein is disclosed.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: October 7, 1997
    Assignee: Cornell Research Foundation, Inc.
    Inventors: Andre Jagendorf, Heriberto Cerutti
  • Patent number: 5674723
    Abstract: The present invention concerns DNA sequences which are suitable for immortalizing human or animal cells, processes for isolating such DNA sequences as well as processes for producing immortalized human or animal cells using such a DNA.
    Type: Grant
    Filed: February 2, 1995
    Date of Patent: October 7, 1997
    Assignee: Boehringer Mannheim GmbH
    Inventors: Hinrich Johann Abken, Klaus Willecke, Herbert Jungfer, Heinrich Barchet
  • Patent number: 5674733
    Abstract: A method of introducing expressible heterologous DNA into Prevotella ruminicola is provided. The method involves conjugal transfer of a shuttle vector comprising the heterologous DNA operatively linked to a promoter functional in P. ruminicola. The invention also provides shuttle vectors for use in the method and P. ruminicola produced by the method. The invention further provides a tetracycline resistance gene of the TetQ class, or fragments thereof that confer tetracycline resistance, and a protein of the TetQ class that provides resistance to tetracycline by protecting ribosomes from tetracycline, or active fragments thereof. Finally, the invention provides a promoter functional in P. ruminicola and an engineered P. ruminicola comprising expressible foreign DNA.
    Type: Grant
    Filed: December 2, 1993
    Date of Patent: October 7, 1997
    Assignee: Biotechnology Research and Development Corporation
    Inventors: Abigail A. Salyers, Nadja B. Shoemaker, Mikeljon P. Nikolich
  • Patent number: 5672493
    Abstract: This invention relates to cells that demonstrate characteristics of tissue macrophages (CCTM), including all substances obtained therefrom, such CCTM are induced from human fibroblasts (HF) by the Snyder-Theilen feline sarcoma virus (ST:FeSV(FeLV)) and are used for the treatment of immunodeficient states. A method for the de novo induction of cells that demonstrate characteristics of tissue macrophages (CCTM) from human fibroblasts (HF), said method comprising isolating and converting HF cultures from human organs, most conveniently skin, performing transformation assays on said HF cultures by transducing with said ST:FeSV(FeLV)-derived DNA sequences, including the corresponding gene products, to demonstrate conversion of HF to CCTM, and to establish the objects and advantages for the production and use of CCTM and CCTM-associated substances in molecular immunotherapy, somatic cell therapy, and gene therapy.
    Type: Grant
    Filed: October 8, 1993
    Date of Patent: September 30, 1997
    Inventor: Levy Kopelovich
  • Patent number: 5672500
    Abstract: A substantially pure protein that is a member of the apoptotic Ced-3/Ice cysteine protease gene family, Mch2.alpha., and an inactive isoform of it, Mch2.beta., are disclosed. Isolated nucleic acid molecules that encode Mch2.alpha. and Mch2.beta., respectively, are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with the protein or the nucleic acid molecules are disclosed. Fragments of nucleic acid molecules that encode Mch2.alpha. and Mch2.beta. having at least 10 nucleotides and oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides are disclosed. Recombinant expression vectors that comprise the nucleic acid molecule that encode Mch2.alpha. or Mch2.beta., and host cells that comprise such recombinant vectors are disclosed. Antibodies that bind to an epitope on Mch2.alpha. and/or Mch2.beta. are disclosed. Methods of identifying inhibitors, activators and substrates of Mch2.alpha.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: September 30, 1997
    Assignee: Thomas Jefferson University
    Inventors: Gerald Litwack, Emad S. Alnemri, Teresa Fernandez-Alnemri
  • Patent number: 5672479
    Abstract: The present invention relates to the PUR protein, nucleotide sequences and expression vectors encoding PUR, and to methods for inhibiting PUR activity. Inhibitors of PUR activity may be used to treat hyperproliferative diseases such as cancer.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 30, 1997
    Assignee: Mount Sinai School of Medicine
    Inventors: Edward M. Johnson, Andrew D. Bergemann
  • Patent number: 5672498
    Abstract: The present invention provides human corneal epithelial cell lines with extended lifespan. The cell lines are useful as an in vitro model of the human ocular surface. Methods for making and using the cell lines are also provided.
    Type: Grant
    Filed: December 28, 1993
    Date of Patent: September 30, 1997
    Assignee: The Gillete Company
    Inventors: Tracey L. Walker, Carolyn R. Kahn
  • Patent number: 5672494
    Abstract: This invention provides methods of increasing the frequency of contact between vectors and stationary target cells in an apparatus containing them which involves causing the vectors to move towards the target cells with motion above and beyond random Brownian motion. The methods of this invention include causing the vectors to move in the direction of the cells by (1) causing flow-through of a liquid containing the vectors through or past a cell bed, (2) moving charged vectors towards the target cells by electrodiffusion and (3) centrifuging vectors and cells to cause settling of vectors onto the cells.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: September 30, 1997
    Assignee: The University of Michigan
    Inventors: Bernhard .O slashed.. Palsson, Michael F. Clarke, Alice S. Y. Chuck
  • Patent number: 5670333
    Abstract: Expression vector for expressing the E. coli a polypeptide other than E. coli malate dehydrogenase coded for by a DNA coding sequence. The vector includes a DNA coding for the polypeptide and also includes an initiation codon wherein the DNA sequence is operatively linked to an upstream sequence located upstream of the initiation codon and which is capable of controlling expression of the polypeptide. The upstream sequence consists on the 285 base pair sequence defined by SEQ ID NO:3. A process for expressing a polypeptide by culturing a host strain of E. coli transformed with an expression vector of the invention is also provided.
    Type: Grant
    Filed: July 28, 1994
    Date of Patent: September 23, 1997
    Assignee: Public Health Laboratory Service Board
    Inventors: Richard M. Alldread, David J. Nicholls, Michael D. Scawen, Tony Atkinson
  • Patent number: 5670361
    Abstract: This invention provides an infectious retrovirus having inserted between the 5' and 3' long terminal repeat sequences of the retrovirus a nucleic acid encoding an anti-HIV-type specific agent under the control of a pol III promoter. Host cells containing the retroviral vectors of this invention also are provided. Further provided are methods of interfering with or preventing HIV viral replication in a cell infected with HIV or likely to be infected with HIV.
    Type: Grant
    Filed: May 17, 1994
    Date of Patent: September 23, 1997
    Assignee: The Regents of the University of California
    Inventors: Flossie Wong-Staal, Mang Yu, Osamu Yamada, Joshua O. Ojwang, Markley C. Leavitt, Anthony Ho
  • Patent number: 5667970
    Abstract: The present invention relates to a method of ordering DNA fragments in which binary overlap information, obtained by determining whether pairs of fragments hybridize to each other, is used to build a "spanning path" across a parent DNA molecule by successively attaching cloned fragments which overlap. The relative position of the many other, non-path fragments is not essential information, but can be determined. Means for eliminating false positives and false negatives is provided. The overlap relationships between fragments may be depicted as an interval graph.
    Type: Grant
    Filed: May 10, 1994
    Date of Patent: September 16, 1997
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Peisen Zhang